KPC Pharmaceuticals (SHSE:600422) Moat Score: 0/10 (As of Jul. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600422 KPC Pharmaceuticals Inc SHSE:600422
66 GF Score
Price ¥8.95
GF Value ¥11.94
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is KPC Pharmaceuticals Moat Score?

KPC Pharmaceuticals has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

KPC Pharmaceuticals has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes KPC Pharmaceuticals might have No Moat - No discernible moat.

KPC Pharmaceuticals  (SHSE:600422) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

KPC Pharmaceuticals Moat Score Related Terms

SHSE:600422
66GF Score
KPC Pharmaceuticals Inc SHSE:600422
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is KPC Pharmaceuticals (SHSE:600422) Overvalued in 2026?

Based on GuruFocus' analysis, KPC Pharmaceuticals stock appears to be undervalued. The current stock price of ¥8.95 is trading 25% below its estimated GF Value™ of ¥11.94. GuruFocus considers KPC Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for SHSE:600422:

  • Moat Score: 0
  • GF Value™: ¥11.94 vs. price of ¥8.95 (25% below fair value)
  • GF Score™: 66/100 with 7 warning signs

No single metric tells the full story. See the SHSE:600422 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

KPC Pharmaceuticals Business Description

Address No. 166 Keyi Road, State New and High-Technology Development Zone, Kunming, Yunnan, CHN, 650106
KPC Pharmaceuticals Inc is a pharmaceutical company which focused on innovative natural botanical drugs in China. Its business scope covers traditional Chinese medicine, chemical medicine, and medicinal circulation. Its products include Panax notoginseng, gastrodine, artemether, and special botanical drugs.
66GF Score

Get the complete analysis for SHSE:600422

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥8.95
Price
¥11.94
GF Value